Medical Schemes Industry Presentation



Similar documents
PRESENTATION TO THE HEALTH MARKET INQUIRY

Medical Scheme Competitor Financial Analysis

Prescribed phase-in solvency levels as per Regulation 29

Private health care cost containment and supply-side regulation. CMS presentation to the Health Portfolio Committee 2014

FACT SHEET The Competition Commission s Market Inquiry into the Private Health Care Sector

Prescribed phase-in solvency levels as per Regulation % 25.0% 20.0% 15.0% 10.0% 5.0% 0.0% Year 1 Year 2 Year 3 Year 4 Year 5

Real Time Monitoring of Schemes

THE MARKET INQUIRY INTO THE PRIVATE HEALTH CARE SECTOR

EXECUTIVE SUMMARY THE SOUTH AFRICAN MEDICAL ASSOCIATION S. Submission to the. Competition Commission Market Inquiry into Private Healthcare

June Discovery Health Medical Scheme Operating Model and Governance Review

Lead Provider Framework Draft Scope. NHS England / 13/12/13 Gateway Ref: 00897

COMPETITION TRIBUNAL REPUBLIC OF SOUTH AFRICA. Case No: 84/LM/Oct04. In the matter concerning the large merger between: Momentum Group Ltd.

Low-Cost Options in Medical Schemes

BAHRAIN TELECOMMUNICATIONS COMPANY B.S.C. AUDIT COMMITTEE CHARTER

How To Understand The Growth In Private Health Insurance

Methods of financing health care

PROPOSED MEDICAL SCHEME AMALGAMATION

UPDATED FREQUENTLY ASKED QUESTIONS SECOND DRAFT REGULATIONS ON THE DEMARCATION BETWEEN HEALTH INSURANCE POLICIES AND MEDICAL SCHEMES 17 JULY 2014

P O Box 6006 Roggebaai WESTERN CAPE Page 1

Guidelines on preparation for and management of a financial crisis

Rating Methodology Life / Health Insurance

Guide to Prescribed Minimum Benefits 2016

COUNTRY CASE STUDY HEALTH INSURANCE IN SOUTH AFRICA. Prepared by: Vimbayi Mutyambizi Health Economics Unit, University of Cape Town

Health Insurance Premiums for Seniors

1. The Council for Medical Schemes

NATIONAL TREASURY STRATEGIC PLAN 2011/14

Corporate Governance Report

California Primary Care Association 2012 New CFO Boot Camp

The South African short term insurance industry By Trevor Barsdorf, Analyst at Global Credit Ratings

The Healthcare market in Brazil

1. Understand the nature of the group risk market Understand the nature and purpose of the different types of employee benefits 3

Solvency II: An update on implementation

CIRCULAR 13 OF 2014: MANAGED CARE ACCREDITATION - FINAL MANAGED HEALTH CARE SERVICES DOCUMENT

ASO. BlueCross BlueShield of Oregon HOW AN ADMINISTRATIVE SERVICES ONLY (ASO) PLAN CAN WORK FOR YOU AN INTRODUCTION FOR GROUPS OF MT HOOD

Re: Inquiry into the Private Health Insurance Legislation Amendment (Base Premium) Bill 2013

PPACA, COMPLIANCE & THE USA MARKET

COMPETITION IN THE AUSTRALIAN PRIVATE HEALTH INSURANCE MARKET

The CCG Assurance Framework: 2014/15 Operational Guidance. Delivery Dashboard Technical Appendix DRAFT

Cloud Computing: An enabler of IT in Indian Healthcare Sector. Media Briefing September 29, 2010

UNDERSTANDING PARTICIPATING WHOLE LIFE INSURANCE

Health Care Worldwide

Metal Industries Provident Fund Surplus Apportionment Information Booklet

International Financial Reporting for Insurers: IFRS and U.S. GAAP September 2009 Session 25: Solvency II vs. IFRS

NOTICE 158 OF 2014 FINANCIAL SERVICES BOARD REGISTRAR OF LONG-TERM INSURANCE AND SHORT-TERM INSURANCE

SOUTH AFRICAN COMPANIES ACT: CHAPTER , 124 Fundamental Transactions, Takeovers And Offers

UNIT TRUST TERMS AND CONDITIONS EFFECTIVE 24 MAY 2016 VERSION 7.1

Rating Methodology for Domestic Life Insurance Companies

1. INTRODUCTION AND PURPOSE

BENEFITS BROCHURE Nurture your health

INSURANCE RATING METHODOLOGY

Health Care Worldwide. Citi - European Credit Conference September 24, London

Rating Methodology. Alternative Investment Funds Open-Ended Real Estate Funds. June Contact

Skill Levels for Delivering High Quality Asthma and COPD Respiratory Care by Nurses in Primary Care

Accountable Care Organization Workgroup Glossary

Key Features of Budget Employee specific Copyright JB ARSEN

3 ABSENTEEISM AND INCAPACITY GETTING EMPLOYEES BACK TO WORK OR COPING WITH THE FACT THAT THEY WILL NEVER RETURN

FULL ANALYSIS I. SUBSTANTIVE ANALYSIS

Mandatory Private Health Insurance as Supplementary Financing

Scott s Real Estate Investment Trust. Interim Consolidated Financial Statements (Unaudited) March 31, 2009 and 2008

Rating Methodology by Sector. Life Insurance

The Provision of Consultancy: Debt Data Collection and Presentation

ASX Statement & Media Release

Dr Ina Diener Physiotherapy Clinician in Private Practice Lecturer in OMT Stellenbosch, South Africa

Analyzing the Statement of Cash Flows

The Travelers Companies, Inc. Workers Compensation Advantage

Health Care Worldwide

APHA Response to the Draft Report (Sept 2014) The Competition Policy Review Australian Private Hospitals Association ABN

Diploma in Business Competence. Learning outcomes for the Diploma in Business Competence (EBCL)

The facts about rising health care costs Underlying medical costs drive growth

mr. M.G.F.M.V. Janssen Secretary to the Managing Board T: I:

Letter to shareholders 1. Quarter of

Risk Management Metrics Subgroup. Embedded Value Definition

Transcription:

Global Credit Rating Co. Medical Schemes Industry Presentation Marc Chadwick 28 October 2015 1

Agenda 1. Brief background to GCR 2. Membership trends 3. Financial and operating performance 4. Medical scheme credit ratings 5. Operating & regulatory environment Key topical issues/views 6. GCR s outlook 2

Background to GCR Established in 1996 as Duff & Phelps Africa Renamed Global Credit Ratings in 2001, to expand and specialise in Emerging Markets Full service rating agency Regional offices in 3 African countries Market leadership established in Africa International institutional shareholders - DEG/KFW group, French government owned PROPARCO 3

Private sector penetration SA population versus private beneficiaries 55,000,000 50,000,000 45,000,000 40,000,000 35,000,000 30,000,000 25,000,000 20,000,000 15,000,000 10,000,000 5,000,000 0 17.0 16.5 16.0 15.5 15.0 14.5 14.0 2001 2007* 2011 Mid 2014 Population Private beneficiaries % Private beneficiaries / Population 4

Medical vs short term insurance penetration 5

Open vs restricted schemes 160 Number of schemes 140 120 100 80 60 40 20 0 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 No. of open schemes No. of restricted schemes Total no. of schemes Linear (No. of open schemes) 6

Consolidation January 2010, PUREhealth liquidated, Medicover merged with Liberty, and Telemed amalgamated with BESTmed. October 2010, Oxygen merged with Medshield, liquidation of Gen-health - Medshield absorbed most members. August 2012, Resolution concluded merger with NIMAS. January 2013, Bonitas merged with Pro Sano. March 2013, Discovery merged with Nampak (closed), followed by merger between Discovery and IBM in July. BESTmed merged with Sappi (closed) April 2013. Discovery & Altron November 2013 7

Consolidation Top 5 open schemes represent 79% of membership from 50% a decade ago GCR expects industry consolidation to continue amidst persistent healthcare cost pressures Benefits of scale; negotiating power Market could still exist for some small niche schemes Consolidation positively considered by GCR as schemes have generally become financially more stable 8

Membership 6000000 5000000 4000000 3000000 2000000 Membership trends 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 1000000 0 Open scheme principal members Restricted scheme principal members Open scheme beneficiaries Restricted scheme beneficiaries 9

Membership 30 Membership trends 25 20 15 10 5 0-5 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Open scheme principal members Open scheme beneficiaries Restricted scheme principal members Restricted scheme beneficiaries 10

Membership government Segmental composition of principal membership 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2007 2008 2009 2010 2011 2012 2013 2014 Government Private sector 11

Membership 3,000 Principal members Membership - GEMS vs top 4 open schemes Beneficiaries 2,500 2,000 1,500 1,000 Discovery Bonitas Medihelp Medshield GEMS 500 0 2007 2008 2009 2010 2011 2012 2013 2014 2007 2008 2009 2010 2011 2012 2013 2014 12

Membership Average beneficiaries by administrator (no. schemes administered) 11% 7% 28 13 27% 3% 4 9 13 Discovery Health Metropolitan Health Medscheme Momentum 14 9 Self administered Other 27% 25% 13

Membership 35 34 33 32 31 30 29 28 27 Average beneficiary age 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Average age open schemes Average age restricted schemes Average age combined 14

Contribution trends 16 14 12 10 8 6 4 2 0 CPI vs medical contribution increases 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Average CPI Contribution Rate Increase Real increase 15

Claims expenditure % 100 90 80 70 60 50 40 30 20 10 0 Risk benefits 6 6 15 14 41 41 6 6 24 24 6 6 2013 2014 Other benefits Medicines Hospitals (excl. medicines) Support professionals Dental specialists Dentists Medical specialists General practitioners 16

Claims expenditure 100% Medical savings benefits paid 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 33% 34% 34% 34% 34% 35% 36% 17% 17% 16% 17% 17% 17% 17% 21% 21% 20% 20% 20% 21% 20% 14% 14% 16% 16% 16% 14% 15% 2008 2009 2010 2011 2012 2013 2014 Medicines Hospitals (excl. medicines) Support professionals Dental specialists Medical specialists Dentists General practitioners Other Benefits 17

Claims expenditure (open) Rands 300 270 240 210 180 150 120 90 60 30 0 Average contributions and claims PMPM 2009 2010 2011 2012 2013 2014 NPI Claims 18

Claims expenditure Key drivers PMBs New medication and technological advancements Increased disease burden Benefit abuse / fraud Corrective measures Enhanced risk management procedures and ongoing benefit design (ongoing process) Schemes have established their own DSP networks (hospital, GP, specialists), in particular for PMB diagnosis & treatment Switch from patent to generic drugs for chronic 19

Delivery costs (open) 16 Delivery cost composition / GPI (%) 14 12 10 8 6 2.1 1.3 1.7 2.1 1.3 1.7 2.3 2.3 2.2 1.5 1.4 1.5 1.4 2.0 2.0 4 2 0 7.6 7.4 7.0 6.6 6.5 2010 2011 2012 2013 2014 Administration fees Acquisition costs Managed care fees Other management expenses 20

Financial performance (open) Net healthcare and net result (Rbn) Financial performance (%) 2,500 4.0 2,000 1,500 1,000 500 2.0 0-500 -1,000-1,500 2009 2010 2011 2012 2013 2014 0.0 2009 2010 2011 2012 2013 2014 Net healthcare result Net result Net annual surplus : net premium income (RHS) 21

Liquidity (open) 5 Cash coverage ratios (months) 4 3 2 2009 2010 2011 2012 2013 2014 Net Gross 22

Statutory solvency Statutory solvency requirement Accumulated funds expressed as a % of GPI (minimum of 25%) In GCRs view, this measure has various shortcomings; doesn t accurately convey overall scheme financial position, risks etc Should be risk based, incorporating balance sheet strength and asset/liability composition, underlying member risk profile etc ICU schemes on close monitoring by CMS Close monitoring justified for rapidly falling solvency CMS approach submit business plan and monthly/quarterly management accounts to CMS, trustees attend regular monitoring meetings 23

Statutory solvency 24

Accumulated funds Rand (billion) Accumulated Funds 50,000 45,000 40,000 35,000 30,000 25,000 20,000 15,000 10,000 5,000 0 47% 46% 48% 48% 47% 46% 46% 47% 45% 46% 55% 54% 53% 54% 54% 53% 52% 52% 54% 53% 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 Accumulated funds - Open schemes Accumulated funds - Restrcited schemes 25

Accumulated funds (open) Reserves per principal member (Rands) 4.9 Accumulated funds : Ave monthly claims (x) 10,000 4.8 8,000 4.7 4.6 6,000 4.5 4,000 4.4 4.3 2,000 4.2 4.1 0 2007 2008 2009 2010 2011 2012 2013 2014 4.0 2007 2008 2009 2010 2011 2012 2013 2014 Reserves per member (Accumulated funds per principal member) Accumulated funds: Ave monthly claims 26

Ratings 3 Key areas to consider when selecting a medical scheme: 1. Price vs benefit / product offering 2. Service 3. Financial strength Rating agency focuses on financial strength: - Ratings reflect an independent opinion of a company s financial position, as well as how the financial position may change in the future (under reasonable & stressful scenarios) 27

Process of assigning ratings Procedure Gathering of information, including historical operational & financial records, industry specific & economic data Desk top analysis Relevant risks, financials & forecasts Meetings with management, in-depth information discussed Draft rating report compiled & forwarded to management Feedback from management obtained, a rating panel is convened & relevant issues discussed, ratings accorded Ratings communicated directly to management Ongoing monitoring & contact with management is crucial in maintaining the integrity of the ratings accorded 28

Credit ratings Benefits of medical scheme ratings Increased pool of members Increased distribution network - Note: a number of leading intermediaries in SA wont place business with medical schemes that don t carry a minimum GCR rating. Management benefit Useful in business development 29

Medical scheme rating definitions Claims paying ability ( CPA ) rating scale: AAA - Highest CPA AA band - Very high CPA A band - High CPA BBB band - Adequate CPA BB band - Moderate CPA B band - Speculative to a high degree CCC - Scheme has been, or is likely to be, placed under order of the court Notes: Categories further subdivided by a +/- Industry risk ceilings Rating watch, or positive or negative rating outlook 30

Credit ratings 31

Credit ratings 32

National Health Insurance Operating & regulatory environment Government has a long term horizon (NHI phased in over 14 years) Clarity so far only on initial stage (building and preparation) increasing health budgets to rehabilitate public healthcare infrastructure (hospitals, nursing homes etc), bolstering human resource capacity Initial stage: general taxes will remain primary funding mechanism; thereafter funding uncertain (VAT and/or income/company tax) Risks: Role of schemes? Loss of younger, healthy members? Top up cover only? Short term: don t expect impact on private sector schemes/administrators Medium term: Opportunities for schemes/administrators? Service provider arrangements could be extended to upgraded public health institutions; Opportunity for schemes to build relationship with public sector; look at success of GEMS Long term: opportunities for schemes/administrators to be involved in NHI? Administrative aspect; existing platform; sharing of skills, data, expertise? Ultimately cost vs benefits/quality healthcare 33

Operating & regulatory environment Prescribed Minimum Benefits 2011: unsuccessful court challenges by BHF i.e. scheme tariff vs invoiced cost CMS opinion unchanged: schemes must pay for PMBs in full at invoice price However, CMS has approached DoH regarding possible amendments to Medical Schemes Act, which could see some compromise? In the interim, PMBs expected to continue to drive elevated medical inflation (in particular hospital, medicine and specialist costs) These higher claims factored into contribution increases (spiral effect) Competition Commission s inquiry into rising medical costs (and system abuse) and the negative impact on affordability/sustainability of the industry expected to be finalised in 2016. Positive findings would likely be beneficial to schemes and their members 34

Operating & regulatory environment Demarcation Goal: Establish clear distinction between medical schemes & health insurance Address the risk of possible harm caused by s/t insurers drawing younger, healthier members away from medical schemes ( gap cover impacting cross subsidisation) Regulations on demarcation between health insurance policies and medical schemes expected late 2015. While gap cover and hospital cash plan insurance is expected to remain, this must rather complement medical schemes as opposed to a negative effect Current vs future impact on schemes is uncertain, but not deemed significant 35

Outlook Overall - GCR has a stable outlook for the sector, expect ratings to generally remain sound Expect key financial metrics (solvency & liquidity) to be upheld Ongoing risk management interventions and enhanced management oversight is expected to continue delivering sustainable benefits & stable claims trends for foreseeable future Industry consolidation expected to continue Regulatory outlook presents certain challenges albeit unresolved 36

Closing Thank you 37